Aerovate Therapeutics
Donna has more than two decades of regulatory experience in the pharmaceutical industry, with deep expertise in designing and implementing regulatory strategies for delivering new medicines to patients. Prior to operating a regulatory affairs consultancy, Donna spent 35 years with AstraZeneca, where she led the development and implementation of global regulatory strategies supporting the approval of new treatments for asthma, COPD, rhinitis, and atrial fibrillation, as well as for new device platforms, and was responsible for interactions with health authorities related to NDA/MAA submissions.
This person is not in any offices
Aerovate Therapeutics
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease.